FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency By Ogkologos - February 18, 2026 127 0 Facebook Twitter Google+ Pinterest WhatsApp Patients should be tested for genetic variants of DPYD prior to initiating treatment Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Man Gives Up His First-Class Seat For 88-Year-Old Woman, Makes Her... November 16, 2021 This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Consuming Poultry Could Lower Your Breast Cancer Risk As Much As... August 22, 2019 A Novel Model Helps Better Predict Risk of Cancer Development in... April 15, 2024 Load more HOT NEWS Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas Dunkin’ Customer Surprises Homeless Employee With Fully Furnished Home Cancer in My Community: How People With Cancer Access Care in... Test Detects Early Signs of Remaining Cancer in Kids Treated for...
